Do analysts recommend BCLI or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BCLI or LTRN?

Lantern Pharma is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A Lantern Pharma N/A N/A -$17.12M -$1.45 N/A

Is BCLI or LTRN more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Lantern Pharma N/A -198.34% -129.08%

Do analysts prefer BCLI or GNTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BCLI or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is BCLI or GNTA more profitable?

Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Genenta Science N/A N/A N/A

Do analysts recommend SGMO or BCLI?

Sangamo Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Sangamo Therapeutics is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate BCLI or ESLA?

Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,007.11%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, BCLI or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is BCLI or ESLA more profitable?

Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Estrella Immunopharma N/A N/A -397.36%

Do analysts prefer TVGN or BCLI?

Tevogen Bio presently has a consensus price target of $100.00, indicating a potential upside of 1,445.60%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Tevogen Bio is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, TVGN or BCLI?

Tevogen Bio is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A

Is TVGN or BCLI more profitable?

Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% Brainstorm Cell Therapeutics N/A N/A -519.50%

Brainstorm Cell Therapeutics (BCLI) Competitors

$0.79 0.00 (0.00%)

As of 08/7/2026 03:46 PM Eastern

Compare

BCLI vs. LTRN, GNTA, SGMO, ESLA, and TVGN

Should you buy Brainstorm Cell Therapeutics stock or one of its competitors? MarketBeat compares Brainstorm Cell Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainstorm Cell Therapeutics include Lantern Pharma (LTRN), Genenta Science (GNTA), Sangamo Therapeutics (SGMO), Estrella Immunopharma (ESLA), and Tevogen Bio (TVGN). These companies are all part of the "biotechnology" industry.

How does Brainstorm Cell Therapeutics compare to Lantern Pharma?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lantern Pharma had 2 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for Lantern Pharma and 0 mentions for Brainstorm Cell Therapeutics. Lantern Pharma's average media sentiment score of 0.21 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
Lantern Pharma	Neutral

Brainstorm Cell Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

Lantern Pharma is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Lantern Pharma	N/A	-198.34%	-129.08%

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 8.5% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Lantern Pharma beats Brainstorm Cell Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Genenta Science?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

In the previous week, Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
Genenta Science	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Brainstorm Cell Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Genenta Science	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Summary

Genenta Science beats Brainstorm Cell Therapeutics on 6 of the 6 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Sangamo Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A

Sangamo Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Sangamo Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

In the previous week, Sangamo Therapeutics' average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Brainstorm Cell Therapeutics	Neutral

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sangamo Therapeutics beats Brainstorm Cell Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Estrella Immunopharma?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,007.11%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Estrella Immunopharma	N/A	N/A	-397.36%

In the previous week, Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled Estrella Immunopharma'saverage media sentiment score.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
Estrella Immunopharma	Neutral

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Brainstorm Cell Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Summary

Estrella Immunopharma beats Brainstorm Cell Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Tevogen Bio presently has a consensus price target of $100.00, indicating a potential upside of 1,445.60%. Given Tevogen Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Tevogen Bio is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 65.6% of Tevogen Bio shares are owned by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tevogen Bio has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

In the previous week, Tevogen Bio's average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score.

Company	Overall Sentiment
Tevogen Bio	Neutral
Brainstorm Cell Therapeutics	Neutral

Tevogen Bio is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A

Summary

Brainstorm Cell Therapeutics beats Tevogen Bio on 5 of the 9 factors compared between the two stocks.

Get Brainstorm Cell Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCLI vs. The Competition

Export

Metric	Brainstorm Cell Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.76M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.23	9.02	270.62	25.05
Price / Sales	N/A	1,291.78	659.52	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	-0.58	17.52	11.20	6.43
Net Income	-$11.62M	-$13.25M	$3.45B	$348.10M
7 Day Performance	-0.30%	5.00%	3.40%	2.66%
1 Month Performance	-27.07%	-2.13%	-0.72%	-0.85%
1 Year Performance	35.82%	61.43%	77.41%	23.96%

Brainstorm Cell Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCLI Brainstorm Cell Therapeutics	N/A	$0.79 flat	N/A	+35.8%	$8.76M	N/A	N/A	40	Upcoming Earnings Gap Up
LTRN Lantern Pharma	0.7081 of 5 stars	$2.75 +5.4%	N/A	-42.7%	$33.30M	N/A	N/A	20	Upcoming Earnings
GNTA Genenta Science	0.6405 of 5 stars	$1.27 -9.9%	N/A	-65.3%	$33.26M	N/A	N/A	7
SGMO Sangamo Therapeutics	1.0463 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
ESLA Estrella Immunopharma	2.1204 of 5 stars	$0.70 +0.6%	$8.00 +1,036.4%	-12.2%	$30.12M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCLI) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. LTRN, GNTA, SGMO, ESLA, and TVGN

How does Brainstorm Cell Therapeutics compare to Lantern Pharma?

Summary

How does Brainstorm Cell Therapeutics compare to Genenta Science?

Summary

How does Brainstorm Cell Therapeutics compare to Sangamo Therapeutics?

Summary

How does Brainstorm Cell Therapeutics compare to Estrella Immunopharma?

Summary

How does Brainstorm Cell Therapeutics compare to Tevogen Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. LTRN, GNTA, SGMO, ESLA, and TVGN

How does Brainstorm Cell Therapeutics compare to Lantern Pharma?

Do analysts recommend BCLI or LTRN?

Does the media prefer BCLI or LTRN?

Which has more volatility & risk, BCLI or LTRN?

Which has better earnings & valuation, BCLI or LTRN?

Is BCLI or LTRN more profitable?

Do insiders & institutionals believe in BCLI or LTRN?

Summary

How does Brainstorm Cell Therapeutics compare to Genenta Science?

Does the media prefer BCLI or GNTA?

Do analysts prefer BCLI or GNTA?

Do insiders & institutionals hold more shares of BCLI or GNTA?

Which has more volatility & risk, BCLI or GNTA?

Is BCLI or GNTA more profitable?

Which has stronger valuation & earnings, BCLI or GNTA?

Summary

How does Brainstorm Cell Therapeutics compare to Sangamo Therapeutics?

Which has more risk and volatility, SGMO or BCLI?

Which has stronger valuation & earnings, SGMO or BCLI?

Do analysts recommend SGMO or BCLI?

Is SGMO or BCLI more profitable?

Does the media prefer SGMO or BCLI?

Do insiders & institutionals have more ownership in SGMO or BCLI?

Summary

How does Brainstorm Cell Therapeutics compare to Estrella Immunopharma?

Do analysts rate BCLI or ESLA?

Is BCLI or ESLA more profitable?

Does the media refer more to BCLI or ESLA?

Do institutionals & insiders have more ownership in BCLI or ESLA?

Which has higher earnings and valuation, BCLI or ESLA?

Which has more risk and volatility, BCLI or ESLA?

Summary

How does Brainstorm Cell Therapeutics compare to Tevogen Bio?

Do analysts prefer TVGN or BCLI?

Do institutionals & insiders have more ownership in TVGN or BCLI?

Which has more risk & volatility, TVGN or BCLI?

Is TVGN or BCLI more profitable?

Does the media favor TVGN or BCLI?

Which has preferable earnings & valuation, TVGN or BCLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools